AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7712918 — intervention group
Group type: COMPARATOR
Intervention: Intravenous cyclophosphamide pulses (IV‐CTX)
Number of subjects: 30
Study 3068846 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine
Number of subjects: 0
Study 3068846 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine
Number of subjects: 0
Study 30452004 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational DVD
Number of subjects: 0
Study 26335915 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvanted influenza vaccine (MF-59)
Number of subjects: 68
Study 26335915 — intervention group
Group type: COMPARATOR
Intervention: Nonadjuvanted influenza vaccine
Number of subjects: 68
Study 26286337 — intervention group
Group type: EXPERIMENTAL
Intervention: Stribild(®) (switch group)
Number of subjects: 0
Study 26286337 — intervention group
Group type: COMPARATOR
Intervention: Continuation of existing regimen (no-switch group)
Number of subjects: 0
Study 23066663 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral PUVA
Number of subjects: 35
Study 23066663 — intervention group
Group type: COMPARATOR
Intervention: Oral PUVA sol
Number of subjects: 35
Study 20464480 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum cholesterol levels
Number of subjects: 302
Study 20464480 — intervention group
Group type: EXPERIMENTAL
Intervention: High-density lipoprotein
Number of subjects: 302
Study 20464480 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-density lipoprotein
Number of subjects: 302
Study 20464480 — intervention group
Group type: EXPERIMENTAL
Intervention: Triglycerides with alcohol consumption
Number of subjects: 302
Study 20464480 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary cholesterol levels
Number of subjects: 302
Study 18718735 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy or radiotherapy
Number of subjects: 282
Study 18718735 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoneurological symptoms
Number of subjects: 282
Study 18718735 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper gastrointestinal symptoms
Number of subjects: 282
Study 18718735 — intervention group
Group type: COMPARATOR
Intervention: Demographic and clinical variables
Number of subjects: 282
Study 17161740 — intervention group
Group type: EXPERIMENTAL
Intervention: Aplisol
Number of subjects: 1203
Study 17161740 — intervention group
Group type: COMPARATOR
Intervention: Tubersol
Number of subjects: 1203
Study 14535966 — intervention group
Group type: EXPERIMENTAL
Intervention: Active nasal continuous positive airway pressure (nCPAP) treatment
Number of subjects: 101
Study 14535966 — intervention group
Group type: COMPARATOR
Intervention: Sham placebo (control)
Number of subjects: 101
Study 10891987 — intervention group
Group type: EXPERIMENTAL
Intervention: Presymptomatic HD gene carriers (PSGCs)
Number of subjects: 216
Study 10891987 — intervention group
Group type: COMPARATOR
Intervention: Nongene carriers (NGCs)
Number of subjects: 216
Study 8938176 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenprocoumon treatment
Number of subjects: 49
Study 8938176 — intervention group
Group type: COMPARATOR
Intervention: Control group (no phenprocoumon)
Number of subjects: 49
Study 8278667 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional bandwidth knowledge of results (BW KR)
Number of subjects: 48
Study 8278667 — intervention group
Group type: EXPERIMENTAL
Intervention: Reversed bandwidth knowledge of results (BW KR)
Number of subjects: 48
Study 8278667 — intervention group
Group type: COMPARATOR
Intervention: Yoked control groups
Number of subjects: 48
Study 3571046 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 750 mg orally every 12 h on days 1‐7
Number of subjects: 8
Study 3571046 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 750 mg orally every 12 h on days 6‐14
Number of subjects: 8
Study 31267818 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 280
Study 29247452 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenous platelet concentrate (APC) applied additionally in test defects
Number of subjects: 25
Study 29247452 — intervention group
Group type: COMPARATOR
Intervention: Guided tissue regeneration (GTR) without APC in control defects
Number of subjects: 25
Study 29247452 — intervention group
Group type: EXPERIMENTAL
Intervention: Test sites with APC
Number of subjects: 25
Study 29247452 — intervention group
Group type: COMPARATOR
Intervention: Control sites without APC
Number of subjects: 25
Study 27431050 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-step facilitation
Number of subjects: 471
Study 27431050 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-randomization measures of perceived benefit of 12-step groups
Number of subjects: 471
Study 27431050 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-randomization 12-step attendance
Number of subjects: 471
Study 27431050 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-randomization perceived benefit and problem severity
Number of subjects: 471
Study 27431050 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-randomization perceived barriers to 12-step groups
Number of subjects: 471
Study 27431050 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-randomization involvement in self-help activities
Number of subjects: 471
Study 22974466 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotarix™ (two or three doses at 10 and 14 weeks)
Number of subjects: 4417
Study 22974466 — intervention group
Group type: COMPARATOR
Intervention: Placebo (three doses at 6, 10, 14 weeks)
Number of subjects: 4417
Study 20608066 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoflavin tablets
Number of subjects: 0
Study 18207018 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-specific immunomodulation therapy (IMT)
Number of subjects: 2426
Study 18207018 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2426
Study 18207018 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-specific immunomodulation therapy (IMT) in patients with no history of previous myocardial infarction (n=919)
Number of subjects: 2426
Study 18207018 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-specific immunomodulation therapy (IMT) in patients with NYHA II heart failure (n=689)
Number of subjects: 2426
Study 16014394 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive group
Number of subjects: 0
Study 16014394 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative group
Number of subjects: 0
Study 16014394 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 12825173 — intervention group
Group type: EXPERIMENTAL
Intervention: GBS II-TT (3.6 micro g of CPS)
Number of subjects: 75
Study 12825173 — intervention group
Group type: EXPERIMENTAL
Intervention: GBS III-TT (12.5 micro g of CPS)
Number of subjects: 75
Study 12825173 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalent GBS II-TT/III-TT vaccine
Number of subjects: 75
Study 12825173 — intervention group
Group type: COMPARATOR
Intervention: GBS II-TT or GBS III-TT monovalent vaccines
Number of subjects: 75
Study 10662983 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous epidural analgesia (EA) with local anaesthetics (bupivacaine 0.125% or ropivacaine 0.2%) and fentanyl 4.5 microg/ml, flow rate 4-10 ml/h
Number of subjects: 50
Study 10662983 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled intravenous analgesia (PCA) with piritramid (bolus 2.5 mg, lock out 15 minutes, maximum of 25 mg/4 h, no background infusion)
Number of subjects: 50
Study 8861830 — intervention group
Group type: EXPERIMENTAL
Intervention: Prrikweg gel
Number of subjects: 100
Study 8861830 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 100
Study 1634056 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous vasoactive intestinal polypeptide (VIP) at doses of 1.5, 3, and 5 pmol.kg‐1.min‐1
Number of subjects: 10
Study 1634056 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 1634056 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-adrenergic agonist isoproterenol
Number of subjects: 10
Study 3966411 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fat plus SPE group (n = 13)
Number of subjects: 36
Study 3966411 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (n = 11)
Number of subjects: 36
Study 3966411 — intervention group
Group type: COMPARATOR
Intervention: Low fat diet group (n = 12)
Number of subjects: 36
Study 31337441 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial extracorporeal shock wave therapy (rESWT) combined with a specific rehabilitation program (RP)
Number of subjects: 40
Study 31337441 — intervention group
Group type: COMPARATOR
Intervention: Sham-rESWT combined with a specific rehabilitation program (RP)
Number of subjects: 40
Study 29765102 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg oral CBD
Number of subjects: 30
Study 29765102 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 30
Study 26706862 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproheptadine (4 mg 3 times per day for 7 days)
Number of subjects: 0
Study 26706862 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24906647 — intervention group
Group type: EXPERIMENTAL
Intervention: Videoconferencing
Number of subjects: 31
Study 24906647 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face interaction
Number of subjects: 31
Study 22123705 — intervention group
Group type: EXPERIMENTAL
Intervention: Lersivirine coadministered with raltegravir
Number of subjects: 0
Study 22123705 — intervention group
Group type: EXPERIMENTAL
Intervention: Lersivirine coadministered with maraviroc
Number of subjects: 0
Study 21186535 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group (Leep combined with drugs)
Number of subjects: 144
Study 21186535 — intervention group
Group type: COMPARATOR
Intervention: Non-treatment group
Number of subjects: 144
Study 21186535 — intervention group
Group type: COMPARATOR
Intervention: Secondary high-risk HPV non-treatment group
Number of subjects: 144
Study 21186535 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary high-risk HPV treatment group (Leep combined with drugs)
Number of subjects: 144
Study 21186535 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical therapy (Leep)
Number of subjects: 144
Study 21186535 — intervention group
Group type: COMPARATOR
Intervention: Drug therapy
Number of subjects: 144
Study 21186535 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical + Drugs
Number of subjects: 144
Study 18672632 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-sewn method
Number of subjects: 117
Study 18672632 — intervention group
Group type: COMPARATOR
Intervention: Stapled method
Number of subjects: 117
Study 18672632 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-sewn method (small esophagus)
Number of subjects: 117
Study 18672632 — intervention group
Group type: COMPARATOR
Intervention: Stapled method (small esophagus)
Number of subjects: 117
Study 15741571 — intervention group
Group type: EXPERIMENTAL
Intervention: biennial FOBT (delivered by mail)
Number of subjects: 26882
Study 15741571 — intervention group
Group type: EXPERIMENTAL
Intervention: biennial FOBT (delivered by general practitioner or a screening facility)
Number of subjects: 26882
Study 15741571 — intervention group
Group type: EXPERIMENTAL
Intervention: patient's choice of FOBT or 'once‐only' sigmoidoscopy
Number of subjects: 26882
Study 15741571 — intervention group
Group type: EXPERIMENTAL
Intervention: 'once‐only' sigmoidoscopy
Number of subjects: 26882
Study 15741571 — intervention group
Group type: EXPERIMENTAL
Intervention: sigmoidoscopy followed by biennial FOBT
Number of subjects: 26882
Study 12879275 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term antibiotic therapy with doxycycline
Number of subjects: 0
Study 12879275 — intervention group
Group type: COMPARATOR
Intervention: Mycoplasma blood infection
Number of subjects: 0
Study 10188068 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate access to therapy
Number of subjects: 0
Study 10188068 — intervention group
Group type: COMPARATOR
Intervention: Watching-waiting control group
Number of subjects: 0
Study 7532074 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia textbook (MMTB)
Number of subjects: 267
Study 7532074 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional lecture
Number of subjects: 267
Study 7532074 — intervention group
Group type: EXPERIMENTAL
Intervention: Printed textbook
Number of subjects: 267
Study 7532074 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 267
Study 1942930 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified therapy consisting of rotation of 6 non cross‐resistant drug combinations with 12 different agents.
Number of subjects: 305
Study 1942930 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of intensive therapy for poor responders (children with more than 10% blasts in the BM on day 28).
Number of subjects: 305
Study 1942930 — intervention group
Group type: EXPERIMENTAL
Intervention: Good responders (children with less than or equal to 10% blasts in the BM on day 28).
Number of subjects: 305
Study 1942930 — intervention group
Group type: EXPERIMENTAL
Intervention: Remission status on day 28 in high-risk patients above one year of age.
Number of subjects: 305
Study 7006118 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of cefuroxime plus 1 g of probenecid
Number of subjects: 178
Study 7006118 — intervention group
Group type: COMPARATOR
Intervention: 5 x 10(6) units of benzyl penicillin plus 1 g of probenecid
Number of subjects: 178
Study 7006118 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg of cefuroxime plus 1 g of probenecid
Number of subjects: 178
Study 7006118 — intervention group
Group type: COMPARATOR
Intervention: 1.5 g of cefuroxime alone
Number of subjects: 178
Study 30802609 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant CO2 insufflation (Con)
Number of subjects: 95
Study 30802609 — intervention group
Group type: COMPARATOR
Intervention: Subsequent CO2 insufflation (Sub)
Number of subjects: 95
Study 27717057 — intervention group
Group type: EXPERIMENTAL
Intervention: Open access aftercare by breast care nurses (Intervention n = 56)
Number of subjects: 112
Study 27717057 — intervention group
Group type: COMPARATOR
Intervention: Standard breast clinic aftercare (Control n = 56)
Number of subjects: 112
Study 26303188 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl buccal tablets (FBTs)
Number of subjects: 263
Study 26303188 — intervention group
Group type: COMPARATOR
Intervention: Oral morphine (OM)
Number of subjects: 263
Study 24424709 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular olanzapine
Number of subjects: 122
Study 24424709 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular haloperidol
Number of subjects: 122
Study 24424709 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular levomepromazine
Number of subjects: 122
Study 22654195 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based level 3 testing followed by 1 wk of autoPAP
Number of subjects: 373
Study 22654195 — intervention group
Group type: COMPARATOR
Intervention: In-laboratory studies (LAB)
Number of subjects: 373
Study 18534491 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly cross-linked polyethylene
Number of subjects: 54
Study 18534491 — intervention group
Group type: COMPARATOR
Intervention: Traditional polyethylene
Number of subjects: 54
Study 17327934 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg
Number of subjects: 40
Study 17327934 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg
Number of subjects: 40
Study 17327934 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 80 mg
Number of subjects: 40
Study 17327934 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 15 mg
Number of subjects: 40
Study 17327934 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg
Number of subjects: 40
Study 17327934 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 60 mg
Number of subjects: 40
Study 17327934 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole (all doses)
Number of subjects: 40
Study 17327934 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean 24-h median intragastric pH
Number of subjects: 40
Study 15471182 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganciclovir (Cymevene) for three months (combined intravenous and oral)
Number of subjects: 133
Study 11577950 — intervention group
Group type: EXPERIMENTAL
Intervention: CHX‐Alc (0.2% chlorhexidine solution)
Number of subjects: 12
Study 11577950 — intervention group
Group type: EXPERIMENTAL
Intervention: CHX‐NaF (0.12% chlorhexidine plus 0.05% sodium fluoride)
Number of subjects: 12
Study 11577950 — intervention group
Group type: EXPERIMENTAL
Intervention: CHX‐CPC‐Zn (0.05% chlorhexidine plus 0.05% cetylpyridinium chloride plus 0.14% zinc lactate)
Number of subjects: 12
Study 11577950 — intervention group
Group type: COMPARATOR
Intervention: Control (no mouthrinse)
Number of subjects: 12
Study 9647303 — intervention group
Group type: EXPERIMENTAL
Intervention: MRC prognostic index score of 1-10
Number of subjects: 236
Study 9647303 — intervention group
Group type: EXPERIMENTAL
Intervention: MRC prognostic index score of 11-15
Number of subjects: 236
Study 9647303 — intervention group
Group type: EXPERIMENTAL
Intervention: MRC prognostic index score of 16-20
Number of subjects: 236
Study 9647303 — intervention group
Group type: EXPERIMENTAL
Intervention: MRC prognostic index score of 21-25
Number of subjects: 236
Study 9647303 — intervention group
Group type: EXPERIMENTAL
Intervention: MRC prognostic index score of 26-33
Number of subjects: 236
Study 9647303 — intervention group
Group type: EXPERIMENTAL
Intervention: MRC prognostic index score of 34-38
Number of subjects: 236
Study 9647303 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaplastic astrocytoma
Number of subjects: 236
Study 9647303 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 236
Study 7921323 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 491
Study 2636680 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary protein restriction (DPR) group (0.4 to 0.6 g/kg/day)
Number of subjects: 248
Study 2636680 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 248
Study 2636680 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary protein restriction (DPR) group
Number of subjects: 248
Study 360902 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (ribavirin)
Number of subjects: 66
Study 360902 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 31154595 — intervention group
Group type: EXPERIMENTAL
Intervention: Transthoracic echocardiography (TEE) before and after marathon running
Number of subjects: 212
Study 31154595 — intervention group
Group type: EXPERIMENTAL
Intervention: Real time three-dimensional echocardiography (RT3DE)
Number of subjects: 212
Study 28575010 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected women
Number of subjects: 1744
Study 28575010 — intervention group
Group type: COMPARATOR
Intervention: HIV-uninfected women
Number of subjects: 1744
Study 25989868 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa 2 µg/kg
Number of subjects: 0
Study 25989868 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa 10 µg/kg
Number of subjects: 0
Study 22562545 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (50‐60 min of circuit weight training per day, 3 days a week, for 12 weeks)
Number of subjects: 20
Study 22562545 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 20
Study 24501827 — intervention group
Group type: EXPERIMENTAL
Intervention: Thinking about death
Number of subjects: 0
Study 24501827 — intervention group
Group type: COMPARATOR
Intervention: Control topic (not specified)
Number of subjects: 0
Study 19196366 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (2000 IU per day)
Number of subjects: 33
Study 19196366 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 16650622 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive/reward intervention (cash lottery for BAC < 0.05)
Number of subjects: 702
Study 16650622 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-intervention parties)
Number of subjects: 702
Study 15249347 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-blocker therapy
Number of subjects: 0
Study 11211198 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA-NL (cyclosporine microemulsion)
Number of subjects: 380
Study 11211198 — intervention group
Group type: COMPARATOR
Intervention: CsA-SM (oil-based formulation of cyclosporine)
Number of subjects: 380
Study 9686458 — intervention group
Group type: EXPERIMENTAL
Intervention: Failure feedback
Number of subjects: 2
Study 9686458 — intervention group
Group type: EXPERIMENTAL
Intervention: Success feedback
Number of subjects: 2
Study 9686458 — intervention group
Group type: EXPERIMENTAL
Intervention: No feedback
Number of subjects: 2
Study 8036289 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxitropium bromide 100 micrograms
Number of subjects: 12
Study 8036289 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxitropium bromide 200 micrograms
Number of subjects: 12
Study 8036289 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxitropium bromide 400 micrograms
Number of subjects: 12
Study 8036289 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2663319 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine (4 mg dose)
Number of subjects: 10
Study 2663319 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 29129436 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide (20 μg once daily)
Number of subjects: 680
Study 29129436 — intervention group
Group type: COMPARATOR
Intervention: Risedronate (35 mg once weekly)
Number of subjects: 680
Study 27147514 — intervention group
Group type: COMPARATOR
Intervention: recAP 200, 500, 1000 or 2000 U/kg (single dose)
Number of subjects: 51
Study 27147514 — intervention group
Group type: COMPARATOR
Intervention: recAP 500 or 1000 U/kg (multiple doses)
Number of subjects: 51
Study 27147514 — intervention group
Group type: COMPARATOR
Intervention: recAP (various doses)
Number of subjects: 51
Study 27147514 — intervention group
Group type: COMPARATOR
Intervention: recAP (250, 500, 1000 U/kg once every 24h for three consecutive days)
Number of subjects: 51
Study 24585907 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapler closure
Number of subjects: 53